Healthcare · Pharmaceuticals & Biotechnology
QVM read Quality business Quality Strong, Valuation Expensive, Momentum Neutral
Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.
Ipca Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. The company manufactures and markets more than 350 finished-dosage formulations and around 80 active pharmaceutical ingredients (APIs), covering therapeutic areas that include pain management, rheumatology, antimalarials, cardiovascular medicine, dermatology and anti-diabetics, and has an emerging biosimilars business. Its products are sold in over 100 countries, and it is one of India's larger API exporters, supplying more than 70 countries.
Source: Wikipedia
Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.
PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.
Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.
Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.
Ranks #15 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.
| Filed | Person | Category | Type | Quantity | Value |
|---|---|---|---|---|---|
| 18 Feb 2026 | MANISH KUMAR JAIN | Other | Sell | 0 | ₹0 |
| 25 Aug 2025 | Pawan Kothari | Employee / designated person | Sell | 0 | ₹0 |
| 21 Aug 2025 | Kaygee Investments Private Limited | Promoter group | Buy | 0 | ₹0 |
| 21 Aug 2025 | Mexin Medicaments Pvt. Ltd. | Promoter group | Sell | 0 | ₹0 |
| 21 Aug 2025 | Paschim Chemicals Private Limited | Promoter group | Sell | 0 | ₹0 |
| 19 Dec 2024 | Mrs. Usha M. Chandurkar | Other | Sell | 0 | ₹0 |
| 12 Mar 2024 | Paschim Chemicals Private Limited | Promoter group | Buy | 0 | ₹0 |
| 20 Nov 2023 | Mr. Ajit Kumar JainAADPJ2602A | Other | Sell | 0 | ₹0 |
| 19 Sep 2022 | E J BABU | Other | Sell | 0 | ₹0 |
| 4 Aug 2022 | Mrs. Usha Chandurkar | Promoter group | Buy | 0 | ₹0 |
| Date | Client | Deal | Action | Quantity | Price | Exchange |
|---|---|---|---|---|---|---|
| 18 Dec 2024 | USHA MADHUKAR CHANDURKAR | Bulk | Sell | 4,000,000 | 1501.5200 | BSE |
| 25 Oct 2022 | ISHARES MSCI INDIA SMALL-CAP ETF | Block | Buy | 68,372 | 900.3500 | BSE |
| 25 Oct 2022 | ISHARES INDIA SC MAURITIUS COMPANY | Block | Sell | 68,372 | 900.3500 | BSE |
| 25 Oct 2022 | ISHARES CORE MSCI EMERGING MARKETS ETF | Block | Buy | 148,105 | 900.3500 | BSE |
| 25 Oct 2022 | ISHARES CORE EMERGING MARKETS MAURITIUS CO | Block | Sell | 148,105 | 900.3500 | BSE |
| 17 Oct 2022 | ISHARES INDIA SC MAURITIUS COMPANY | Block | Sell | 34,160 | 889.4500 | BSE |
| 17 Oct 2022 | ISHARES MSCI INDIA SMALL-CAP ETF | Block | Buy | 34,160 | 889.4500 | BSE |
| 17 Oct 2022 | ISHARES CORE MSCI EMERGING MARKETS ETF | Block | Buy | 232,725 | 889.4500 | BSE |
| 17 Oct 2022 | ISHARES CORE EMERGING MARKETS MAURITIUS CO | Block | Sell | 232,725 | 889.4500 | BSE |
| 11 Oct 2022 | ISHARES MSCI INDIA SMALL-CAP ETF | Block | Buy | 25,053 | 912.0500 | BSE |
Quarterly results, AGMs, buybacks and other board-approved business.
| Date | Purpose | Results |
|---|---|---|
| 13 Aug 2026 | Financial Results | Yes |
| 29 May 2026 | Financial Results/Dividend | Yes |
| 13 Feb 2026 | Financial Results | Yes |
| 13 Nov 2025 | Financial Results | Yes |
| 11 Aug 2025 | Financial Results | Yes |
Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.
Data unavailable.
Data unavailable.
Board of directors and corporate information →
Single-stock futures available for this stock -- OI buildup, PCR, Max Pain and Greeks are all on the full F&O page.
Part of: NIFTY 500, NIFTY 500, NIFTY MIDCAP 150, NIFTY MIDCAP 150, NIFTY PHARMA, NIFTY PHARMA
The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.
The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.
The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.
No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.
